Immunis publishes research study showing reversal of aging muscle deficits

IRVINE, Calif., August 15, 2022 /PRNewswire/ — Immunis Inc., a private biotechnology company developing a novel treatment for age- and disease-related immune decline, announced the peer-reviewed publication in GeroScience research conducted by Professor Micah Drummond to University of Utah to study the efficacy of Immunis’ immunomodulatory secretome product on aged skeletal muscle.

A consequence of aging is a decline in the health of the immune system. The degeneration of the immune system manifests many degenerative conditions in the body, including muscle atrophy. Sarcopenia significantly affects quality of life and is an important risk factor for disability and mortality with age. Mitigating muscle loss and improving muscle recovery are unmet medical needs.

Professor Drummond’s independent research has shown that Immunis’ immunomodulatory secretome product, IMM01-STEM, improved muscle mass and strength during disuse and recovery in aged mouse models. Aged mice received intramuscular injections of IMM01-STEM under three experimental conditions: ambulation, amyotrophy or recovery after amyotrophy. Compared to control-treated aged mice, IMM01-STEM treatment resulted in greater soleus muscle mass, increased muscle fiber cross-sectional area, and improved grip strength for all three experimental conditions. There was also a decrease in collagen and an increase in muscle stem cells, indicating an enhanced muscle remodeling response. Additionally, administration of IMM01-STEM to cultured rodent muscle cells increased myotube size and enhanced myonuclei incorporation into myotubes.

“Due to its multi-component molecules associated with cell function and tissue remodeling, I would not be surprised if IMM01-STEM has beneficial effects on other age-related diseases,” Professor Drummond said.

Together, these findings demonstrate that Immunis’ immunomodulatory secretome improves muscle size and strength after atrophy. Immunis has been approved by the United States Food and Drug Administration to conduct a Phase 1/2a clinical trial of IMM01-STEM in muscle atrophy in patients with knee osteoarthritis (KOA).

KOA is a local and systemic inflammatory disease that is one of the main causes of disability in the elderly. Muscle atrophy is the primary underlying cause of this reduced mobility, with muscle dysfunction accelerating cartilage deterioration in patients.

For more information on Immunis’ Phase 1/2a IMM01-STEM trial, please visit:

About Immunis Inc.

Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age- and disease-related immune decline. The STEM product line leverages Immunis’ cutting-edge capabilities in stem cell technologies to deliver a product of all-natural, human immune modulators in their natural relative physiological concentrations.

SOURCE Immunis, Inc.

Paul N. Strickland